Medication

Search for

Medication research papers

Prescribing in Parkinson's disease: a story of hope and adverse eventsA review of National Health Service spending in England on prescription drugs used in Parkinsonism over the last 10 years shows that spending has risen rapidly and that newly introduced drugs are quickly and expensively adopted. This paper explores the gains and costs of such prescribing. 01 October 2012
Parkinson's disease medication use and costs following deep brain stimulationPD medication use and costs decreased following DBS in either target over 36 months, but cumulative costs were less for STN than for GPi. 15 September 2012
Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's diseaseLEDD, levodopa daily dose and dopamine agonist daily dose were not related to smoking or caffeine intake status. Authors found a weak correlation between caffeine daily intake and pramipexole dose. 07 September 2012
Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug developmentThe aim of the present review is to give an overview of neuroprotective agents being currently investigated for the treatment of AD, PD, HD and ALS in clinical phases. 01 September 2012
Role for α6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian miceTo conclude, the similar declines in L-dopa-induced AIMs in nicotine-treated wildtype mice and in α6(-/-) mice treated with and without nicotine indicate an essential role for α6β2* nAChRs in the maintenance of L-dopa-induced AIMs. These findings suggest that α6β2* nAChR drugs have potential for reducing L-dopa-induced dyskinesias in Parkinson's disease. 01 September 2012
Duodenal levodopa/carbidopa infusion therapy in patients with advanced PD leads to improvement in caregivers' stress and burdenConclusions: Duodenal levodopa infusion-related clinical improvement in patients with advanced PD leads to substantial reductions in caregivers' stress and burden. 01 September 2012
Beyond Motor Symptoms Impact of Continuous Dopaminergic Stimulation on Non-motor and Social Aspects of Advanced Parkinson'sTwo patient cases are presented here that illustrate the benefits of continuous dopaminergic stimulation on the non-motor symptoms of Parkinson's disease. 01 September 2012
The Timing of Continuous Dopaminergic Stimulation for Optimal Clinical OutcomesDelaying treatment with levodopa/carbidopa intestinal gel (LCIG) infusion in patients with severe 'on-off' fluctuations may result in a poorer and slower response, while early initiation of CDS therapy increases the chance of achieving continuous 'on' without dyskinesia. 01 September 2012
Continuous Dopaminergic Stimulation The Evolving Management of Advanced Parkinson's DiseaseThe gold standard of treatment, levodopa, has been widely available to patients since the 1960s, but some of the recently developed advanced therapies are still underused and inaccessible to many patients. While ongoing research has resulted in significant improvements in management, more is needed to delay, stop or even reverse PD. 01 September 2012
Two Decades of Evolving Care with Pump Therapies What have we Learned?Methods have been developed to provide continuous dopaminergic stimulation, such as the delivery of apomorphine by subcutaneous infusion and levodopa/ carbidopa by intestinal gel infusion. These therapies have been shown to significantly reduce 'off' time and improve motor fluctuations, and therefore have been a major advance in the management of PD. 01 September 2012

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ « Previous | Next » ]